Eurobio Scientific SA
PAR:ALERS
Eurobio Scientific SA
Total Equity
Eurobio Scientific SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Equity
€178.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
41%
|
CAGR 10-Years
24%
|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€181.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Equity
-€21.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Equity
€8.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-19%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
€97.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€79.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Total Equity?
Total Equity
178.7m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Total Equity amounts to 178.7m EUR.
What is Eurobio Scientific SA's Total Equity growth rate?
Total Equity CAGR 10Y
24%
Over the last year, the Total Equity growth was 2%. The average annual Total Equity growth rates for Eurobio Scientific SA have been 10% over the past three years , 41% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet